



Neuland FY22 income at Rs.953.2 crore

EBITDA at Rs. 144.3 crore

Hyderabad, India, May 10, 2022 - Neuland Laboratories Limited (NLL) (NSE: NEULANLAB; BSE:524558), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services to customers located in around 80 countries, today announced financial results for the fourth quarter and year ended March 31, 2022.

Commenting on the performance Mr. Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, *“The past financial year was marked by a flat revenue, owing principally to weak GDS offtake from our customers. Given our focus on building execution excellence, we remain confident about the long-term prospects of all our businesses despite facing certain technical issues with some late-stage CMS projects.”*

In addition, Mr. Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Labs added *“Our performance this year was a mixed bag. While our GDS business experienced a revenue decrease due to volume drop in certain key products, our input cost structures experienced an unusual increase. Given our focus on delivering complex projects in line with clients’ technical requirements, we retain our optimism that the overall business will grow in line with our stated expectations and reflect increased margins over the long term.”*

Financial Summary

Rs. crore								
Particulars	Q4FY22	Q3FY22	QoQ Growth (%)	Q4FY21	YoY Growth (%)	FY22	FY21	YoY Growth (%)
Total Income	256.5	238.4	7.6%	259.3	(1.1)%	953.2	953.0	0.0%
EBITDA	39.3	34.2	15.1%	40.0	(1.7)%	144.3	162.5	(11.2)%
EBITDA margin (%)	15.3%	14.3%	100 bps	15.4%	(10) bps	15.1%	17.1%	(200) bps
PAT	21.8	12.7	71.4%	17.2	26.7%	63.5	80.3	(20.9)%
PAT margin (%)	8.5%	5.3%	320 bps	6.6%	190 bps	6.7%	8.4%	(170) bps
EPS (Basic) Rs.	17.0	9.9	71.4%	13.4	26.7%	49.5	62.6	(20.9)%

Q4 FY22 Earnings Call

The company will conduct a one-hour Earnings call at **18:00 hrs. IST on Tuesday, May 10, 2022** where the management will discuss the Company’s performance and answer questions from participants. To participate in this conference call, please register on the Zoom link below:

[Zoom Link](#)

Please note that the transcript of the conference call will be uploaded on the company website in due course.

About Neuland Laboratories Limited

For over 38 years, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 75 APIs and has filed over 903+ Regulatory filings in the US (60 active US DMFs), the European Union (EU) and other geographies. Its manufacturing facilities are inspected and approved by the U.S. FDA and other leading regulatory agencies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI "SID & GP" Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001. For more information, visit www.NeulandLabs.com.

If you have any questions or require further information, please feel free to contact

IR Department at Neuland

Tel: +91 40 6761 1600

Email: ir@neulandlabs.com

Diwakar Pingle, EY IR

Email: diwakar.pingle@in.ey.com